Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase IV Commitments Are Increasingly Delayed, FDA Report Finds

Executive Summary

The rate of delayed postmarketing commitments has increased since 2005, according to data provided in FDA's annual "Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Commitment Studies.

You may also be interested in...



Phase IV Commitments Increasingly Delayed in 2007, FDA Report Finds

Displaying a trend policy-makers hope to reverse through provisions in the FDA Amendments Act, FDA's annual "Report on the Performance of Drug and Biologics Firms in Conducting Post-marketing Commitment Studies" shows that the rate of delayed post-marketing commitments in 2007 has again slightly increased

Phase IV Commitments Increasingly Delayed in 2007, FDA Report Finds

Displaying a trend policy-makers hope to reverse through provisions in the FDA Amendments Act, FDA's annual "Report on the Performance of Drug and Biologics Firms in Conducting Post-marketing Commitment Studies" shows that the rate of delayed post-marketing commitments in 2007 has again slightly increased

New Risk Management Landscape For Drugs Offers Fertile Ground For CROs

The coming year could see the first use of the enhanced safety powers created by the FDA Amendments Act, but 2008 is certain to see a shift in the pharmaceutical industry's development approach as it grapples with the need for more safety data

Related Content

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel